City Therapeutics (NASDAQ:CTY) Coverage Initiated by Analysts at Jefferies Financial Group

Posted by Doug Wharley on Nov 10th, 2026

Analysts at Jefferies Financial Group began coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $32.00 price target on the stock. Jefferies Financial Group‘s target price points to a potential upside of 71.40% from the stock’s current price.

Several other equities research analysts also recently weighed in on CTY. Oppenheimer started coverage on shares of City Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $46.00 target price on the stock. Wall Street Zen raised shares of City Therapeutics to a “hold” rating in a research report on Saturday, October 24th. Three research analysts have rated the stock with a Buy rating. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $37.33.

Get Our Latest Report on City Therapeutics

City Therapeutics Trading Up 2.3%

NASDAQ CTY opened at $18.67 on Tuesday. City Therapeutics has a one year low of $15.81 and a one year high of $23.88.

Insider Transactions at City Therapeutics

In related news, major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of City Therapeutics stock in a transaction on Monday, October 19th. The shares were bought at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the transaction, the insider directly owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Nelsen acquired 170,000 shares of the firm’s stock in a transaction dated Monday, October 19th. The stock was bought at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the purchase, the director directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The disclosure for this purchase is available in the SEC filing.